Tokyo, Sept. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062695) titled 'Intravenous N-acetylcysteine as adjunctive therapy for acute aluminum phosphide poisoning: an updated systematic review of randomized controlled trials' on Sept. 1.

Study Type: Others,meta-analysis etc

Primary Sponsor: Institute - Department of Emergency and Critical Care Medicine, Faculty of Medicine, Osaka Medical and Pharmaceutical University

Condition: Condition - Acute aluminum phosphide poisoning Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To evaluate whether adding intravenous N-acetylcysteine to standard care reduces in-hospital or up-to-30-day all-cause mortality in patients with acute aluminum phosphide poisoning compared with the same standard care alone or the same standard care plus placebo. Secondary objectives are to assess intubation or invasive mechanical ventilation, vasopressor use, shock improvement, and serious adverse events. Basic objectives2 - Safety,Efficacy

Eligibility: Age-lower limit - Not applicable Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Individual- or cluster-randomized controlled trials enrolling patients with acute aluminum phosphide poisoning. The intervention must be intravenous N-acetylcysteine added to standard care, and the comparator must be the same standard care alone or the same standard care plus placebo. Arm-level data for aluminum phosphide poisoning must be separable. No restriction will be placed on age, sex, severity, country, language, or publication status. Key exclusion criteria - Studies of zinc phosphide or other poisons only, or mixed-poison studies without separable arm-level aluminum phosphide data; studies using non-intravenous N-acetylcysteine; studies in which any planned non-N-acetylcysteine cointervention differs between groups; non-randomized or quasi-randomized studies using predictable methods such as alternation, record or patient numbers, birth dates, or admission dates; and duplicate reports of the same trial, which will be linked as one trial family. Target Size - 200

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2026 Year 09 Month 01 Day Anticipated trial start date - 2026 Year 09 Month 01 Day Last follow-up date - 2026 Year 10 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071784

Disclaimer: Curated by HT Syndication.